Atwood & Palmer’s Sage Therapeutics SAGE Stock Holding History

Atwood & Palmer’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-18	Closed	-$1K	–	426
2015 Q3	$1K	Buy	+18	New	+$1.11K	﹤0.01%	423

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Atwood & Palmer's SAGE Position: Q4 2015 in Review

Atwood & Palmer sold out of Sage Therapeutics (SAGE) in Q4 2015, closing a stake of 18 shares — an estimated $1K sold.

Atwood & Palmer first reported a position in SAGE in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 137 funds tracked by Wall St. Rank hold SAGE as of Q4 2015.

Atwood & Palmer reported no remaining Sage Therapeutics position as of Q4 2015 after selling out during the quarter.
Atwood & Palmer sold 18 Sage Therapeutics shares in Q4 2015, an estimated $1K.
Atwood & Palmer first reported a position in Sage Therapeutics in Q3 2015 and held it in 1 quarter.
Atwood & Palmer's Sage Therapeutics position peaked at $1K in Q3 2015.
137 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2015.

Based on Atwood & Palmer's 13F filing for Q4 2015, filed 28 Jan 2016.